Exposure Of Bisphenol Analogues In Chronic Kidney Disease and Dialysis Patients

Shanghai Jiao Tong University

Status: Completed

Conditions: Hemodialysis Complication; Chronic Kidney Diseases

Study type: Observational

Funder types: Other

Identifiers

NCT04100421

BPs

Details and patient eligibility

About

In this retrospective study, the serum levels of Bisphenol A (BPA) and three BPA analogs, namely, bisphenol B (BPB), bisphenol S (BPS), and bisphenol F (BPF), in patients with CKD, patients on dialysis therapy and healthy control were investigated to find out if BPA and BPA analogs accumulates in patients with chronic kidney disease (CKD), and if hemodialysis filters contribute to bisphenol burden in patients on hemodialysis (HD).

Enrollment: 154 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• age 18; informed consent

Exclusion criteria

• absence of active inflammatory, infectious, malignant diseases, acute chronic kidney disease, or pregnancy at the initiation or during the study

Trial design

154 participants in 6 patient groups

Mild renal injury

Description:

CKD patients with eGFR ≥ 60 ml∙min-1∙ (1.73 m2)-1. The eGFR was evaluated by the Chronic Kidney Disease Epidemiology Collaboration (eGFR-EPI).

Moderate renal injury

Description:

CKD patients with eGFR between 30 ml∙min-1∙(1.73 m2)-1 to 60 ml∙min-1∙(1.73 m2)-1. The eGFR was evaluated by the Chronic Kidney Disease Epidemiology Collaboration (eGFR-EPI).

Severe renal injury

Description:

CKD patients with eGFR \< 30 ml∙min-1∙(1.73 m2)-1. The eGFR was evaluated by the Chronic Kidney Disease Epidemiology Collaboration (eGFR-EPI).

Hemodialysis

Description:

uremic patients on hemodialysis therapy

Peritoneal dialysis

Description:

uremic patients on peritoneal dialysis

Healthy control

Description:

Healthy volunteers with no history of kidney diseases or any chronic diseases which may lead to renal injury.